Orbsen Therapeutics Ltd. is a spinout SME from the Regenerative Medicine Institute (REMEDI) of the National University of Ireland, Galway. In the FP7 PURSTEM project, Orbsen developed new technologies for the isolation of stromal cells from adult human tissue. In 2012 Orbsen filed the first series of patents protecting the CD362-technology and applications, and formally initiated pre-clinical work in a series of clinical indications including adult respiratory distress syndrome (ARDS), several diabetic complications, and corneal graft rejection. Orbsen is now developing the novel proprietary CD362 technology that permits the isolation of pure and defined CD362+ stromal stem cells from human tissue, designed to ensure that resulting therapies comply with the forthcoming EMA and UK BSI guidelines on the purity and definition of cellular medicines.
The REDDSTAR, MERLIN, VISICORT and DeCIDE FP7 programs have linked Orbsen to 23 new collaborations with global leaders in the fields of diabetes, MSC immunology and GMP therapy manufacture, Solid Organ Transplant rejection, and haematopoietic stem cell (HSC) development. In addition, Orbsen is collaborating with Prof. Rhodri Ceredig (NUI Galway) as part of a Science Foundation Ireland (SFI) Award to develop immunological potency/batch assays for MSC therapeutic products.